Not available
Quote | AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)
Last: | $0.86 |
---|---|
Change Percent: | 2.36% |
Open: | $0.7811 |
Close: | $0.86 |
High: | $0.8775 |
Low: | $0.7784 |
Volume: | 241,277 |
Last Trade Date Time: | 01/09/2024 03:00:00 am |
News | AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)
2024-01-09 09:10:23 ET More on AcelRx Pharmaceuticals Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for AcelRx Pharmaceuticals Financial information for AcelRx Pharmaceuticals For further details see: AcelRx announ...
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
Message Board Posts | AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)
Subject | By | Source | When |
---|---|---|---|
$ACRX AcelRX Pharmaceuticals Inc | mick | investorshub | 04/30/2023 10:12:48 PM |
$ACRX AcelRX Pharmaceuticals Inc | mick | investorshub | 04/15/2023 6:04:32 PM |
Well , THAT report was ugly .. | molee | investorshub | 03/31/2023 5:34:04 PM |
Loading up .70 for events,30th ,I dont want | 81vette | investorshub | 03/28/2023 5:58:52 PM |
Loading up .70 for events,30th ,I dont want | 81vette | investorshub | 03/28/2023 5:58:50 PM |
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...